Thorax, 78(Suppl
Regulatory agencies increasingly recognize the value of surrogate endpoints, adaptive trial designs, and biomarker-driven patient stratification, particularly in areas of high unmet need
Also showed significant reductions in liver fat (up to 82.4%) and improvements in metabolic parameters Phase 3 (TRIUMPH-4) : The Phase 3 TRIUMPH-4 trial confirmed and exceeded Phase 2 results, demonstrating 28.7% mean weight loss at 68 weeks with the 12 mg dose -- the highest reported for any metabolic peptide in a Phase 3 trial Phase 3 program : Additional Phase 3 trials ongoing for obesity (TRIUMPH-1) and type 2 diabetes (TRANSCEND) MASLD/MASH : Specific trials underway evaluating liver-related endpoints Phase 3 TRIUMPH-4 data have confirmed the Phase 2 promise, though the full Phase 3 program across all indications is still ongoing
Jiang, N., Su, D., Chen, D., Huang, S., Tang, C., Jing, L., Yang, C., Zhou, Z., Yan, Z., & Han, J